The future of computational pathology: expectations regarding the anticipated role of artificial intelligence in pathology by 2030

Running Title: AI in pathology in 2030

M Alvaro Berbís^{1,2,*} David S. McClintock³, Andrey Bychkov⁴, Jerome Y Cheng⁵, Brett Delahunt⁶, Lars Egevad⁷, Catarina Eloy⁸, Alton B Farris III⁹, Filippo Fraggetta¹⁰, Raimundo García del Moral¹¹, Douglas J. Hartman¹², Markus D Herrmann¹³, Eva Hollemans¹⁴, Kenneth A Iczkowski¹⁵, Aly Karsan¹⁶, Mark Kriegsmann¹⁷, Jochen K Lennerz¹⁸, Liron Pantanowitz¹⁹, Mohamed E. Salama²⁰, John Sinard²¹, Mark Tuthill²², Jeroen Van der Laak²³, Bethany Williams²⁴, César Casado-Sánchez^{25,2}, Víctor Sánchez-Turrión^{26,2}, Antonio Luna²⁷, José Aneiros-Fernández^{1,11}, Jeanne Shen^{28,*}

- ¹ Department of R&D, HT Médica, San Juan de Dios Hospital, Córdoba, Spain
- 6 7 8 9 10 112 134 15 16 ² Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
- 17 ³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
- ⁴ Department of Pathology, Kameda Medical Center, Chiba, Japan
- ⁵ University of Michigan, Ann Arbor, MI, USA
- ⁶ Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
- ⁷ Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
- ⁸ Pathology Laboratory, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
- ⁹ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
- ¹⁰ Pathology Unit, Azienda Sanitaria Provinciale Catania, Gravina Hospital, Caltagirone, Italy
- ¹¹ Department of Pathology, San Cecilio Clinical University Hospital, Granada, Spain
- ¹² Department of Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- ¹³ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- ¹⁴ Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands
- ¹⁵ Department of Pathology, Medical College of Wisconsin, Milwaukee, USA
- ¹⁶ Department of Pathology & Laboratory Medicine, University of British Columbia, Michael Smith Genome Sciences Centre, Vancouver, Canada
- ¹⁷ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
- ¹⁸ Department of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
- ¹⁹ Department of Pathology, University of Michigan, Ann Arbor, MI, USA
- ²⁰ Department of Pathology, Sonic Healthcare, Austin, TX, USA
- ²¹ Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
- ²² Department of Medical Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK
- ²³ Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
- ²⁴ Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- ²⁵ Department of Plastic and Reconstructive Surgery, La Paz University Hospital, Madrid, Spain.
- ²⁶ Department of General Surgery and Digestive Tract, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain
- ²⁷ Department of Integrated Diagnostics, HT Médica, Clínica Las Nieves, Jaén, Spain
- ²⁸ Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging, Stanford University School of Medicine, Stanford, CA, USA

45 46 47

1 2

3 4 5

(*) Corresponding authors:

- M Alvaro Berbís
- Department of R&D, HT Médica, San Juan de Dios Hospital, Córdoba 14011, Spain
- Faculty of Medicine, Autonomous University of Madrid, Madrid 28029, Spain
- a.berbis@htime.org
 - Jeanne Shen
 - Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging
- Stanford University School of Medicine, Stanford, CA 94305, United States of America
- jeannes@stanford.edu

Keywords: Artificial intelligence; machine learning; digital pathology; computational pathology;
 anatomic pathology; pathologist workflow

62

63 64 **ABSTRACT**

Background: Artificial intelligence (AI) is rapidly fueling a fundamental transformation in the practice of
pathology. However, AI's clinical integration remains challenging, with no AI algorithms to date enjoying
routine adoption within typical anatomic pathology (AP) laboratories. This survey gathered current
expert perspectives and expectations regarding the role of AI in AP from those with first-hand

- 70 computational pathology and AI experience.
- 71 Methods: Perspectives were solicited using the Delphi method from 24 subject matter experts between
- 72 December 2020 and February 2021 regarding the anticipated role of AI in pathology by the year 2030.
- The study consisted of three consecutive rounds: 1) an open-ended, free response questionnaire
- 74 generating a list of survey items; 2) a Likert-scale survey scored by experts and analyzed for
- consensus; and 3) a repeat survey of items not reaching consensus to obtain further expert consensus.
- **Findings**: Consensus opinions were reached on 141 of 180 survey items (78.3%). Experts agreed that
- Al would be routinely and impactfully used within AP laboratory and pathologist clinical workflows by
- 78 2030. High consensus was reached on 100 items across nine categories encompassing the impact of
- Al on (1) pathology key performance indicators (KPIs) and (2) the pathology workforce and specific
- 80 tasks performed by (3) pathologists and (4) AP lab technicians, as well as (5) specific AI applications
- 81 and their likelihood of routine use by 2030, (6) Al's role in integrated diagnostics, (7) pathology tasks
- 82 likely to be fully automated using AI, and (8) regulatory/legal and (9) ethical aspects of AI integration in
- 83 pathology.
- 84 Interpretation: This is the first systematic consensus study detailing the expected short/mid-term
- 85 impact of AI on pathology practice. These findings provide timely and relevant information regarding
- 86 future care delivery in pathology and raise key practical, ethical, and legal challenges that must be
- 87 addressed prior to Al's successful clinical implementation.
- 88

89 Funding:

- 90 This research received no specific grant from any funding agency in the public, commercial, or not-for-91 profit sectors.
- 92
- 93
- 94

95 INTRODUCTION

96 97 By virtue of its ability to "learn" from large volumes of electronic health record and image data without 98 explicit programming, machine learning and artificial intelligence (AI) are set to fuel an unprecedented 99 transformation in healthcare. In hospitals and clinics of the future, AI will become a cornerstone in the 100 way care is delivered, contributing to more accurate diagnoses, increasingly agile, cost-effective, and standardized clinical workflows, and highly effective and personalized treatments.^{1,2} Excitement and 101 102 expectations regarding the potential of AI to revolutionize healthcare have continued to build, as 103 evidenced by the growing list of medical AI publications in the form of original research articles, review 104 papers, health policy reports, white papers and consensus recommendations from professional societies, and coverage in the popular media.^{1–16} A recent survey of English-language articles indexed 105 106 in PubMed showed a significant increase in the volume of medical AI research publications, from just 107 203 articles in 2005 to 12,563 in 2019.³

108

109 Pathology has attracted growing attention as an image-rich specialty likely to be strongly impacted by 110 recent advances in AI. The development of machine learning-based tools for automated image analysis 111 has led to a surge in AI applications promising to revolutionize current pathology workflows, as well as the advent of a new field, computational pathology.⁷ Between the years 2010-2020, approximately 23% 112 113 (3,398) of all medical AI research publications were in pathology, making it the number one mostpublished specialty among the 17 specialties surveyed.³ A recent survey of the patent landscape from 114 115 the years 1974–2021 yielded 523 patents relevant to the application of AI to digital pathology, with the 116 primary application areas being whole-slide image (WSI) acquisition, segmentation, classification, and 117 object detection.¹⁷ AI has been applied to several popular tasks in anatomic pathology (AP), including 118 diagnosis, prognostication, and biomarker quantification, with key examples being automated assessment of prognostic biomarkers such as Ki-67 in breast cancer,^{18–20} automated tumor grading in 119 120 prostate cancer.^{21–25} and diagnosis of metastatic breast cancer in lymph nodes.^{26–29} Other recently-121 explored AI applications in pathology have included tools for optimizing clinical laboratory workflows. such as automated quality control (QC).^{30–32} 122

123

Much of the growth in computational pathology has been facilitated by the increased adoption of digital pathology, providing large amounts of WSI data as a prerequisite for practical AI model development and validation.³³ Concurrently, use of digital workflows within pathology has provided practices with new platforms for testing and integrating computational pathology tools within AP workflows, generating greater interest in AI from pathologists and pathology trainees. A 2018 voluntary survey of 487 international pathologists and pathology trainees revealed a generally positive attitude towards AI, with

nearly 75% expressing interest/excitement regarding the integration of AI tools into diagnostic
pathology.³⁴ Furthermore, 80% of respondents predicted the integration of AI-based assistance into AP
workflows within the next 5–10 years.³⁴ Numerous reviews have been published on the emerging and
future applications of pathology AI to cancer diagnosis, prognostication, and treatment response
prediction, metastasis detection in lymph nodes, single and multiplex biomarker quantification, tumor
content/cellularity assessment for molecular testing, mutation status prediction, and a multitude of other
tasks in pathology.^{35–45}

137

138 Despite the recent progress and enthusiasm surrounding the application of AI to pathology, few algorithms are currently in routine clinical use,^{37,46} with a dearth of prospective multi-center, randomized 139 trials present evaluating the impact of these algorithms in clinical settings.^{47,48} Further, ethical concerns 140 141 have been raised regarding potential patient data privacy breaches, biased datasets producing 142 systemic algorithmic bias, potential harm related to erroneous or misleading Al-generated outputs, and exacerbation of healthcare disparities due to unequal access to AI.⁴⁹ All of these factors, along with 143 144 hurdles related to regulatory approval and reimbursement for AI products, have contributed to a significant AI "translation gap" in pathology.³⁷ While much has been written regarding the various 145 146 opportunities and challenges surrounding AI in pathology, to date no systematic survey of opinions 147 exists regarding the direct role of AI in pathology from the short to medium term perspective (the next 148 decade) from those with dedicated expertise in digital and computational pathology. To address this 149 knowledge gap, we conducted a consensus survey to gain detailed insight into the current challenges. 150 expectations, and perspectives surrounding the role of AI in pathology, as seen from the point of view of an international panel of clinically active "early adopters" with hands-on experience developing and 151 152 evaluating the clinical performance and utility of AI algorithms. For the survey, we chose to apply the 153 Delphi method, a robust and widely accepted tool in medicine for building consensus among experts that has been shown to outperform standard statistical methods.^{50,51} 154

155

156 A Delphi study involves a panel of experts who rate a series of statements, usually in a binary (e.g., 157 agree/disagree) or semi-quantitative (e.g., Likert scale) manner. These statements might be produced 158 after a systematic literature search or by surveying the same experts through a preliminary survey with 159 open-ended questions (typically referred to as "Round 1"). Rating of statements is done over multiple 160 consecutive rounds, during which the statements reaching the consensus criterion are omitted from 161 subsequent rounds. Raters are then invited to reconsider their responses based on the group's mean 162 or median ratings from previous rounds. Studies are typically terminated when consensus has been 163 reached, responses are stable, or after a pre-fixed number of rounds (usually two)⁵² to prevent expert 164 fatigue. In contrast to typical single-round surveys, the Delphi technique relies on both the

- anonymization of responses to avoid bias and the use of experts and structured communication
- 166 through an iterative pathway to reach more reliable conclusions.⁵³
- 167

The goals of our study were to: 1) investigate the expected impact of AI on pathology; 2) forecast the extent of clinical AI implementation in the specialty by the end of this decade; and 3) provide specific insights into which technical, legal, regulatory, and ethical aspects of AI integration will require the most attention from pathology laboratories in the coming years. We expect the results of this study to be of broad interest to practicing pathologists, pathology trainees, pathology assistants and laboratory technicians, patients, physicians from other medical specialties, professional societies, hospital administrators, regulatory bodies, and researchers in academia, industry, and government.

175

176 MATERIALS AND METHODS

177 Expert Panel Recruitment

178 Candidates for the expert panel were selected by the research team using the following eligibility

179 criteria: 1) professionals working within the specialty of pathology (anatomic and/or laboratory

180 medicine) with an MD (or equivalent medical degree, such as an MBBS) and/or PhD, and 2) authorship

181 of at least one peer-reviewed publication in the area of CPath/AI within the four years preceding the

- 182 study (2016–2020) indexed in PubMed.
- 183

184 Invitations to participate in the study were sent in December 2020 to 39 candidates meeting the 185 selection criteria. A total of 24 experts (60%) accepted and completed all three rounds of the survey. 186 Detailed characteristics of the panelists are summarized in table 1. The majority of experts were 187 practicing in North America (54%), with the remainder practicing in Europe, Japan, and New Zealand. 188 The panelists were distributed across 10 different pathology subspecialties, with a third of panelists 189 explicitly specializing in informatics, computational pathology, and/or digital pathology. Finally, the 190 range of years in professional practice was mostly spread evenly across the panelists, with the majority 191 having been in practice for 11–20 years (33%).

192

Table 1. Characteristics of the panelists

Categories	n (%)
Country of residence	
United States of America	12 (50%)
The Netherlands	2 (8·3%)
Spain	2 (8·3%)

United Kingdom	1 (4·2%)
Germany	1 (4·2%)
Italy	1 (4·2%)
Sweden	1 (4·2%)
Portugal	1 (4·2%)
Canada	1 (4·2%)
Japan	1 (4·2%)
New Zealand	1 (4·2%)
Area of subspecialization (multiple responses possible)	
Informatics, computational pathology, digital pathology	8 (33·3%)
Hematopathology	4 (16·7%)
Genitourinary pathology	3 (12·5%)
Gastrointestinal pathology	3 (12·5%)
Endocrine pathology	2 (8·3%)
Dermatopathology	2 (8·3%)
Surgical pathology	2 (8·3%)
Molecular pathology	2 (8·3%)
Thoracic pathology	1 (4·2%)
Bone & soft tissue pathology	1 (4·2%)
Years of experience	
0–10	7 (29·2%)
11–20	8 (33·3%)
21–30	7 (29·2%)
31–40	2 (8·3%)


194

195


196 Delphi Study Development

197 To obtain a reliable consensus of opinions, the Delphi study was conducted over three rounds via a

series of detailed questionnaires combined with controlled opinion feedback.⁵⁴ The flowchart for the
study is summarized in **figure 1**.



200



202 203

204 In Round 1, a preliminary review of the pathology AI literature, along with the research team's empirical 205 experience, was used to generate an open-ended questionnaire containing a set of 12 questions 206 geared toward eliciting the ideas and opinions of the expert panelists regarding the following three 207 topics: 1) forecasting the future of AI in pathology, 2) specific AI applications in pathology, and 3) ethical 208 and regulatory aspects (table 2). The panelists' responses to these open-ended questions were 209 combined and distilled (all original answers were analyzed, and similar answers within the same 210 category were grouped and summarized into a single statement, with the original wording used by the 211 panelists reproduced wherever possible) into a series of questionnaire statements used in the 212 subsequent survey rounds. 213 214 Table 2. Round 1 guestions Section 1: Forecasts about the future (please answer according to what you believe will happen

by 2	by 2030, instead of what you would like to see happen)						
1	On what key performance indicators related to pathology do you believe AI will have a positive						
	impact?						
2	How do you think AI will impact the pathology workforce (jobs which will be created and jobs						
	which will be destroyed) by 2030?						
3	What new tasks will pathologists be involved in?						

4	What new tasks will pathology technicians be involved in, or what existing tasks will they take on more responsibility for?
5	Which tasks currently performed by pathologists will be fully automated by AI by 2030?
	tion 2: Applications of AI in pathology (please cite any existing or potential AI-based tools ch, in your opinion, would bring value to pathologists. Be as specific as possible)
6	In what ways can AI be used to improve diagnostic precision?
7	In what ways can AI be used to speed up or facilitate the work of pathologists?
8	What examples of AI tools or applications would bring value to the analysis and interpretation of histological images?
9	What examples of AI tools or applications would bring value to other aspects of the laboratory workflow?
10	In what ways can AI be used to bring value to integrated diagnostics? (integrated diagnostics refers to the convergence of two or more diagnostic techniques, such as pathology, radiology, genomics)
Sec	tion 3: Ethical and regulatory aspects
11	What regulatory challenges will have to be overcome for the generalized adoption of AI in the pathology setting?
12	What ethical issues could arise from the use (and potential misuse) of AI in the pathology setting?
Al, a	rtificial intelligence.

- 215 216
- 217 In Round 2, the panelists were asked to rate each of the questionnaire statements on a 7-point Likert
- scale (from 1 to 7), with different scores designed to fit different categories of questions. For example, a
- score of 1 might indicate "Very strongly disagree", "Impossible" (with regard to likelihood of an event
- 220 occurring), "Disappear" (with regard to job number or availability), or "Not involved at all" (with regard to
- degree of involvement in specific tasks), whereas a score of 7 might indicate "Very strongly agree",
- 222 Certain", "Dramatically increase", or "Daily involvement", depending on the question, with higher scores
- 223 generally representing a more favorable opinion toward the future role or impact of AI on Pathology
- 224 (table 3).
- 225

226 **Table 3.** Likert scales for the different sections (7-point)

Point Score	Agreement scale	Probability scale	Job number variation scale	Involvement scale
1	Very strongly disagree	Impossible	Disappear	Not involved at all
2	Strongly disagree	Very unlikely	Greatly decrease	Rarely involved
3	Disagree	Unlikely	Somewhat decrease	Somewhat involved
4	Neither agree nor disagree	Even chance / neutral	Remain the same	Sometimes involved

5	Agree	Likely	Somewhat increase	Often involved
6	Strongly agree	Very likely	Greatly increase	Routinely involved
7	Very strongly agree	Certain	Dramatically increase	Daily involved

227 228

In Round 3, the panelists were asked to re-rate all statements which did not reach consensus during Round 2. Consensus on statements was defined, a priori, as having an interquartile range (IQR) of less than 1 (IQR \leq 1) for ratings along the 7-point Likert scale.^{55,56} During Round 3, the panelists were shown their Round 2 ratings on each statement, along with the median and IQR for the group as a whole, and finally given the option to change their previous ratings, if desired.

234

All questionnaires were completed via an online Google Form (Google Inc, Mountain View, CA, USA), with individualized links to the form e-mailed to each panelist. The survey participants remained anonymous to one another during all three Rounds, with each participant able to view only their own responses to each statement during Rounds 1 and 2, along with the anonymized group medians and IQRs during Round 3.

240

241 Statistical Analysis

To examine whether any significant differences in panelist scores were present based on gender,

243 practice location, pathology subspecialty, or years in practice, Wilcoxon rank-sum tests (two-tailed,

alpha = 0.05 significance criterion) were performed. All analyses were performed using Microsoft Excel

245 (Microsoft Corporation, Redmond, WA, USA) and STATA v16 (StataCorp LLC, College Station, TX,
246 USA).

247

248 **RESULTS**

249 Survey Rounds

The unstructured first Delphi round allowed the panelists relative freedom in expressing their individual thoughts on topics they felt were important or relevant to the future of AI in pathology over the next decade. This resulted in the generation of 180 summative statements spanning the following nine categories: 1) impact of AI on key performance indicators (KPIs), 2) impact of AI on the pathology

workforce, 3) impact of AI on pathologist tasks, 4) impact of AI on pathology technician tasks, 5)
specific applications of AI in pathology, 6) role of pathology AI in integrated diagnostics, 7) pathology
tasks likely to be fully automated by AI, 8) regulatory and legal aspects of AI integration, and 9) ethical
aspects of AI integration.

258

259 One of the motivations behind using the Delphi method was its ability to achieve greater consensus (a 260 reduction in variance across rounds, as measured by the IQR) among a limited number of expert 261 panelists. After Round 2, responses to 48 of the 180 (26.7%) statements reached consensus (IQR \leq 1). 262 After Round 3, the panelists had reached consensus on 141 of the 180 (78.3%) statements. The mean 263 and median Likert scores across the panelists for each of the 180 statements ranged from 3.04 to 6.83 264 (mean), and from 3 to 7 (median), respectively. Tables 4 through 10 present the 100 statements 265 (spread across seven general categories) that achieved high directional consensus (defined as IQR \leq 266 1, and both mean and median scores of either ≤ 3 or ≥ 5) among the expert panelists. For these 100 267 statements, two-tailed Wilcoxon rank sum tests demonstrated no significant differences in Likert scores 268 between the various panelist comparison groups (female vs. male, North American vs. non-North 269 American, subspecialty informatics or computational/digital pathology vs. other subspecialty, and < 10270 years vs. \geq 11 years in practice) on 85 of the 100 statements. The remaining 15 statements are further 271 discussed in the corresponding sections below, which summarize the most significant results of the 272 survey according to topic/category

273

274 Impact of AI on Pathology Key Performance Indicators (KPIs)

275 In general, there was agreement that AI would help improve laboratory KPIs, such as turnaround time, 276 diagnostic accuracy, the detection rate for rare events (for example, small foci of primary or metastatic 277 tumor), and quality of diagnostic reports (table 4). However, it was also anticipated that histopathologic 278 analyses would become more quantitative, and that diagnostic reports would become more complex. 279 There was also agreement that AI would lead to greater standardization of diagnostic and pre-analytical 280 processes, such as tissue sectioning, staining techniques, and workflows. As a result of these 281 anticipated improvements in KPIs, it was expected that there would be an increase in the satisfaction of 282 referring physicians. A statement regarding the likelihood of the cost per case decreasing with the use 283 of AI failed to reach consensus, although a majority of the experts predicted the cost per case would 284 not decrease with medium term AI use (within the next 8-10 years). In addition, the panelists did not 285 reach consensus on whether the number of second-opinion consultations would decrease as a result of 286 Al adoption.

287

Table 4. Statements on which high directional consensus was reached regarding the impact of AI on pathology key performance indicators (KPIs)

By 2030, due to the integration of AI in the pathology setting					
Key performance indicator	Mean	Median	Result		
Standardization of pre-analytical processes (staining and slicing techniques) will increase	5.38	5	Agree		
Diagnostic accuracy will increase	5.67	6	Strongly agree		
Diagnosis and grading of tumors will be more standardized, bringing more objectivity to the diagnosis of certain entities that are currently subject to high interobserver variability	6.04	6	Strongly agree		
Detection of rare events (small metastases, small tumor foci) will increase	5.88	6	Strongly agree		
Analyses will be more quantitative	6.21	6	Strongly agree		
Completeness of reports will increase	5.13	5	Agree		
Complexity of reports will increase	5.13	5	Agree		
Quality of reports will increase	5.38	5	Agree		

290 AI, artificial intelligence.

291 292

Table 4 presents those statements regarding the impact of AI on pathology KPIs for which there was high directional consensus among the panelists. Overall, these results projected, by the year 2030, growth in computational pathology as a subspecialty with AI applications assisting pathologists in making diagnoses that are more accurate, standardized, objective, quantitative, and complete.

297

298 Impact of AI on the Pathology Workforce and Specific Tasks

299 There was agreement that the number of jobs for pathologists, as well as administrative staff, would 300 likely remain the same. However, a modest increase in the number of jobs for technicians and 301 information technology (IT) professionals was expected. While the size of the overall pathology job 302 market was not expected to vary greatly due to the adoption of AI, the types and frequencies of tasks 303 performed by pathologists and pathology laboratory technicians were expected to change significantly. 304 There was agreement that AI would facilitate subspecialization in pathology, with the number of 305 pathologists specializing in computational pathology greatly increasing. Tables 5 and 6 present the 306 expected impact of AI on the pathologist (table 5) and pathology laboratory technician (table 6) 307 workforces and associated tasks.

- 308
- 309
- 310

311 Table 5. Statements on which high directional consensus was reached regarding the impact of AI on 312 pathologist workforce and tasks

Task	Mean	Median	Involvement/Agreement
The number of jobs for IT staff will	5.54	5	Somewhat increase
The number of specialized "computational" pathologists will greatly increase	5.75	6	Strongly agree
Pathologists will be more involved in diagnostic tumor boards	5.58	6	Strongly agree
Pathologists will be more involved in multidisciplinary conferences	5.63	6	Strongly agree
Pathologists will be more involved in research activities	5.42	5	Agree
Pathologists will be spending more time in the study of rare lesions	5.13	5	Agree
By 2030, due to the integration of AI in the patholo pathologists in these tasks will be		ng, the de	gree of involvement of
Digital pathologic diagnosis without the use of physical glass slides	5.58	6	Routine
Interpretation of computationally derived measurements and evaluations	6.08	6	Routine
Collaboration with EHR teams regarding the use of laboratory data for a wide range of clinical decision support tools	5.25	5.5	Routine
Evaluating different kinds of AI software and deciding whether these are appropriate for their workflow	5.54	6	Routine
Validation and QA/QC of AI solutions	5.63	6	Routine
Validation and QA/QC of AI-rendered diagnoses	5.88	6	Routine

AI, artificial intelligence; IT, information technology; EHR, electronic health record; QA/QC, quality
 assurance/quality control.

315

316

Table 6. Statements on which high directional consensus was reached regarding the impact of AI on pathology lab technician workforce and tasks

By 2030, due to the integration of AI in the pathology setting, the degree of involvement of pathology laboratory technicians in these tasks will be							
Task Mean Median Involvement Lev							
Operation of digital slide scanners, digitization, and image management	6.25	7	Daily				
QA/QC of digitized images	6.08	6.5	Daily				
Digital pathology support for pathologists and other users, such as device calibration	5.88	6	Routine				
Assessing histology consistency, i.e., re-addressing SOPs to make slides and corresponding images more suitable for AI (more consistent tissue and staining quality)	5.83	6	Routine				

Validation and QA/QC of AI-rendered diagnoses	5.17	5	Often
AI, artificial intelligence; SOP, standard operating procedure; QA/	QC, qual	ity assura	ince/quality control.

319 320 321

322 There was agreement that, by 2030, pathologists would be routinely involved in new tasks related to 323 the incorporation of AI into their workflows, such as interpreting diagnostic outputs from AI algorithms, 324 evaluating AI software, and performing validation and guality assurance/guality control (QA/QC) for AI 325 solutions and AI-rendered diagnoses. There was also agreement pathologists would be directly 326 participating in the design and development of AI solutions and, based on the availability of new data 327 generated by AI, they would also be contributing to the definition of new categories of patients. As a 328 result of AI adoption, pathologists were also expected to be more involved in ancillary activities, such as 329 research and participation in multidisciplinary conferences and tumor boards. The panelists also agreed 330 pathologists would sometimes be more involved in meeting directly with patients, including more 331 frequent inclusion in patient treatment decision-making.

332

333 Compared to the panelists who had been in practice for 11 years or longer, those in practice for 10 or 334 fewer years (7 panelists) more strongly agreed that digital pathologic diagnosis without the use of 335 physical glass slides would be routine by 2030 (p = 0.041), with a median score of 7 (compared with a 336 median score of 6, for those with 11 or more years of practice) and mean score of 6.43 (compared to a 337 mean score of 5.23, for those with 11 or more years of practice). The same group also more strongly 338 agreed that interpretation of computationally derived measurements and evaluations would be routine 339 (p = 0.048), with a median score of 7 (compared with a median score of 6, for those with 11 or more 340 years of practice) and mean score of 6.71 (compared to a mean score of 5.82, for those with 11 or 341 more years of practice).

342

The work of pathology technicians was also expected to undergo major changes as a result of Al adoption (**table 6**). Technicians would be routinely involved in tasks related to new digital and computational workflows, such as scanner operation, device calibration, and QA/QC of digitized images. There was no consensus, however, as to whether technicians would be directly participating in Al-assisted diagnosis, although a slight majority of the panelists surveyed thought this would be the case.

349

350 The panelists subspecializing in informatics or computational/digital pathology (8 panelists) more

351 strongly felt that pathology laboratory technicians would routinely be providing digital pathology support

for pathologists and other users (for example, by performing device calibration and other tasks) (p =

353 0.005), with a median score of 7 and a mean score of 6.63 (as compared to a median of 6 and a mean

of 5.50 for those not subspecializing in informatics or computational/digital pathology). Similarly, this group also felt more strongly that pathology laboratory technicians would be routinely involved in assessing and improving the consistency of histologic tissue preparation and staining to make images more suitable for AI (p = 0.049), with a mean score of 6.25 (as compared to a mean of 5.63, with the same median of 6, for those not subspecializing in informatics or computational/digital pathology).

359

360 Applications of AI to Pathology and Integrated Diagnostics

361 Al was expected to positively impact many aspects of the pathology workflow. The panelists proposed 362 several specific applications they thought would likely be in routine use in pathology laboratories by the 363 year 2030 (table 7). Regarding the analysis and interpretation of histologic images, routine applications 364 included algorithms for the identification of hotspot areas (for example, during mitotic counts), detection 365 of microorganisms (such as acid-fast bacilli and Helicobacter pylori) and cancer, and assistance with 366 tumor grading. The panelists were also certain AI would be in routine use for the automated 367 guantification of immunohistochemical (IHC) and immunofluorescent (IF) biomarker stains, such as Ki-368 67, estrogen receptor (ER), progesterone receptor (PgR), and programmed cell death ligand 1 (PD-L1),

as well as the counting of mitotic figures and lymphocytes on hematoxylin and eosin (H&E) stained

- tissue, and the identification of lymph node metastases and, in particular, micrometastases.
- 371

372	Table 7 . Statements on which high directional consensus was reached regarding AI applications in
373	pathology

By 2030, the probability of these AI tools being routinely used in pathology labs is					
AI application	Mean	Median	Likelihood		
Identification of micrometastases	6.17	6.5	Certain		
Detection of lymph node metastases	6.33	7	Certain		
Quantification of IHC or IF stains, such as Ki-67, ER, PgR, PD-L1	6.67	7	Certain		
Quantification of number of mitoses in H&E-stained images	6.33	6.5	Certain		
Counting lymphocytes	6.42	6.5	Certain		
Automated ordering of IHC for specific applications / assisting with selection of immunohistochemical stains needed	5.46	6	Very likely		
Automated QA/QC of IHC positive and negative controls	5.75	6	Very likely		
Proposing specific IHC or other molecular methods to solve a specific diagnostic problem	5.17	5.5	Very likely		
Prioritization of cases (such as cases with neoplasia and infectious organisms in immunosuppressed patients)	5.50	6	Very likely		
Quality control of whole-slide images (scanning process), and detection of poor-quality slides (tissue folds, poor staining)	6.13	6	Very likely		
Quality improvement of whole-slide images	6.00	6	Very likely		

Pre-selecting regions of interest suspicious for cancer for pathologists	6.29	6	Very likely
to view	0.05		Manufikahu
Identification of hotspot areas	6.25	6	Very likely
Detection of microorganisms (AFB, <i>H. pylori</i>)	6.17	6	Very likely
Assisting with tumor grading	6.21	6	Very likely
Quantification of eosinophils in eosinophilic esophagitis	6.13	6	Very likely
Quantitation of features (e.g., fibrosis in various organs, liver steatosis, etc.)	6.29	6	Very likely
Marking of perineural invasion, lymphovascular invasion	5.79	6	Very likely
Automated measurements (e.g., of tumor areas)	6.21	6	Very likely
Ensuring all diagnostically relevant areas on the slide are viewed prior to report finalization	5.42	6	Very likely
Mandatory second reads when the pathologist diagnosis does not match the potential AI diagnosis (within a predefined range/percentage; e.g., if the AI tool detects potential tumor on a biopsy but the pathologist reads the biopsy as no evidence of tumor)	5.79	6	Very likely
Standardization of pathology reports	5.88	6	Very likely
Al-assisted laboratory workflow management, including workload assignments to pathologists, residents, and technicians	5.33	5	Likely
Detection of signet ring-cell cancer	5.29	5	Likely
Pre-selection of potentially cancer-positive samples for pathologist's review, while the bulk of clearly negative samples can be automatically processed	5.13	5	Likely
Triaging of cases to the most appropriate pathologist at the earliest possible time	5.08	5	Likely
Providing a set of differential diagnoses on difficult cases	5.13	5	Likely
Proposing specific additional tests for solving a diagnostic problem (e.g., Al algorithm suggesting STAT6 immunostaining on a spindle cell neoplasm of the pleura)	5.17	5	Likely
Import of contextually-related data on a case for quick review by the pathologist during diagnostic slide review	5.21	5	Likely
Pre-populating relevant report details from the medical record/gross description	5.29	5	Likely
Selection of the appropriate synoptic report based on prior pathology findings, including the current case gross report	5.38	5	Likely
Pre-populating reports based on AI interpretation of images	5.13	5	Likely

AI, artificial intelligence; IHC, immunohistochemistry; IF, immunofluorescence; ER, estrogen receptor;
PgR, progesterone receptor; PD-L1, programmed cell death ligand 1; H&E, hematoxylin and eosin;
QA/QC, quality assurance/quality control; AFB, acid-fast *Bacillus; H. pylori, Helicobacter pylori;* STAT6,
signal transducer and activator of transcription 6.

- 378
- 379

380 Tasks which are currently performed manually, but which were expected to be replaced by AI

automation by the year 2030, included the provision of size measurements (e.g., tumors) and the

detection of perineural and lymphovascular invasion in malignancies. In addition, it was expected that
 Al-based computational/virtual staining would replace the need for multiplex histochemistry and IHC/IF.
 384

385 Within a decade. All was expected to increase diagnostic efficiency by prioritizing regions of interest 386 suspicious for cancer involvement for pathologists to review first, pre-populating relevant diagnostic 387 report fields using data extracted from the medical record and/or gross description, and pre-populating 388 diagnostic reports based on AI interpretation of whole-slide images. In addition, AI was expected to 389 assist pathologists with making more accurate diagnoses by importing contextually relevant clinical 390 history and other data related to a case for quick review by the pathologist during case sign-out, 391 providing a set of differential diagnoses, and prompting second reads on cases where there was a 392 discrepancy between the pathologist diagnosis and the diagnosis rendered by the AI algorithm. 393

The panel also foresaw a significant impact of AI on other aspects of the laboratory workflow. Routine AI-assisted prioritization of cases for pathologist review, suggestions for ancillary stains to be performed, and automated ordering of additional stains were thought to be very likely by 2030 (**table 7**). In terms of differences in opinion between the various panelist subgroups, those subspecializing in informatics or computational/digital pathology less strongly believed that AI would routinely be used for the quantification of eosinophils in eosinophilic esophagitis (*p* = 0.049), with a mean score of 5.75, as compared to a mean of 6.31 (with the same median of 6), for the other subspecialists.

401

402 Al was expected to foster the integration of pathology with other diagnostic modalities, such as 403 radiology and genomics, by: 1) identifying histologic regions of interest to be sampled for genomic 404 testing; 2) correlating morphologic and genomic information to help interpret genetic aberration; 3) 405 comparing tumor extent on histology slides and radiologic images; and 4) interpreting tumor treatment 406 response in radiologic images, based on pathology data. Multimodal-AI was also expected to enable 407 the combination of diverse types of diagnostic data (gross/macroscopic, microscopic, radiologic, and 408 genomic) in a single interface, and to facilitate the use of integrated diagnostic reports for certain 409 diseases, such as prostate cancer (table 8). Consequently, it was felt Al-powered integrated 410 diagnostics would likely lead to significant advances in the personalization of healthcare by creating 411 new categories of patients based on differential risk stratification (prognostic) roadmaps and prediction 412 of clinical outcomes.

413

Table 8. Statements on which high directional consensus was reached regarding the role of AI in
 integrated diagnostics

By 2030, the probability of these integrated diagnostic applications being used routinely is				
AI application	Mean	Median	Likelihood	

Identification of histologic regions to be sampled for genomic testing	5.38	5	Likely
Prediction of biomarker status and clinical outcomes for personalized medicine, based on integrated diagnostics	5.08	5	Likely
Selection of patients with prostate cancer for active surveillance versus radiotherapy/surgery, based on integration of pathology and radiology data	5.00	5	Likely
Creation of new categories of patients by integrating all "big data" from pathology, clinical lab, radiology, and genomics	5.04	5	Likely
Building risk stratification (prognostic) roadmaps for individual patients based on input from histology, radiology, and genomics	5.13	5	Likely
Use of integrated reports for select conditions, e.g., prostate cancer	5.33	5	Likely

- 416 AI, artificial intelligence.
- 417
- 418 419 The panelists with greater practice experience (\geq 11 years) more strongly believed the integration of 420 pathology and radiology data would routinely be used to select patients for active surveillance versus 421 radiotherapy/surgery in prostate cancer (p = 0.044: equal medians of 5 but mean of 5.29 versus 4.29 422 for those with ≥ 11 years and ≤ 10 years of practice experience, respectively). The panelists with more 423 practice experience more strongly believed that AI would routinely be used to build risk stratification 424 (prognostic) roadmaps for patients based on histologic, radiologic, and genomic input data (p = 0.020; 425 equal medians of 5, means of 5.41 versus 4.43 for those with \geq 11 years and \leq 10 years of practice 426 experience, respectively).
- 427
- The panelists felt it was likely that, by 2030, AI would not simply assist with, but would fully replace, pathologists on several manually-performed tasks. Among these were stain selection; measurement tasks; prioritization and triage of cases; screening for microorganisms; colorectal polyp, cervical cytology, and lymph node screening; and grading of breast and colorectal cancers (**table 9**). Assigning work to pathologists, trainees, and technicians, as well as triaging cases to the appropriate pathologist,
- 433 were also deemed likely to be fully automated by AI.
- 434

Table 9. Statements on which high directional consensus was reached regarding pathology tasks
 expected to be fully automated by 2030

By 2030, the probability of these tasks being fully delegated to AI in pathology labs is			
Task	Mean	Median	Likelihood
Verification of positive and negative controls for IHC	5.71	6	Very likely
Prioritization of cases	5.54	6	Very likely
Triage of cases to appropriate pathologists	5.46	6	Very likely

Contextual data lookup on patients from the EHR relevant to the pathology case being reviewed	5.25	6	Very likely
Slide QC (e.g., detection of tissue folds and tears, stain quality evaluation, etc.)	5.88	6	Very likely
Screening for microorganisms, such as AFB and H. pylori	5.96	6	Very likely
Screening of colorectal polyps	5.58	6	Very likely
Cervical cytology screening	6.21	6	Very likely
Screening lymph nodes for metastases	5.83	6	Very likely
Measurement tasks	6.17	6	Very likely
Quantification of IHC or IF stains, such as Ki-67, ER, PgR, PD-L1	6.29	6	Very likely
Quantification of mitotic count on H&E-stained images	6.08	6	Very likely
Bone marrow differential counts	5.54	6	Very likely
MIB-1 scoring	6.04	6	Very likely
Assessing extent of liver steatosis and fibrosis	5.54	6	Very likely
Screening of tissues with a cancer diagnosis to select regions for tissue coring or macroscopic dissection	5.08	5	Likely
Slide screening for regions of interest	5.13	5	Likely
Grading of breast cancer	5.42	5	Likely
Grading of colorectal cancer	5.33	5	Likely

AI, artificial intelligence; IHC, immunohistochemistry; EHR, electronic health record; QC, quality control;
AFB, acid-fast *Bacillus; H. pylori, Helicobacter pylori;* IF, immunofluorescence; ER, estrogen receptor;
PgR, progesterone receptor; PD-L1, programmed cell death ligand 1; H&E, hematoxylin and eosin.

441

The panelists practicing outside of North America (11 panelists) thought it more likely that colorectal

polyp screening would be fully delegated to AI by the year 2030 (p = 0.047; mean = 6 and median = 6

for non-North American panelists, versus mean = 5.23 and median = 5 for North American panelists).

445 Those with more practice experience (≥ 11 years) thought it more likely that mitotic counts on H&E-

stained images would be fully delegated to AI (p = 0.036; equal medians of 6 but mean of 6.29 versus

447 5.57 for those with \geq 11 years and \leq 10 years of practice experience, respectively).

448

449 Regulatory and Ethical Aspects of Al Integration in Pathology

450 The panelists foresaw significant regulatory and ethical challenges posed by the integration of AI in

451 pathology (table 10). While some panelists initially suggested such issues might not pose a challenge

to the application of AI in pathology, since the pathologist (or another physician) always takes the

453 ultimate responsibility for the diagnostic, therapeutic or prognostic use of AI, the final consensus

454 opinion overruled that initial suggestion. In principle, the panel agreed that both primary diagnostic and

455 secondary (e.g., advisory/assistive) algorithms would have to meet strict regulatory requirements.

456 There was agreement that regulatory bodies would create new guidelines addressing the integration of

- 457 Al into pathology, which would provide specific validation procedures and simplify regulatory pathways
- 458 for AI tools, although regulatory clearance of AI software would still be a lengthy and costly process.
- 459
- 460 **Table 10**. Statements on which high directional consensus was reached regarding regulatory and461 ethical aspects

By 2030, regarding the integration of Al in pathology Aspect	Mean	Median	Likelihood
A set of new guidelines will be developed, specifically addressing the integration of AI in pathology	6.63	7	Very strongly agree
Specific validation procedures for different types of AI tools will be defined by regulatory bodies	6.46	7	Very strongly agree
The introduction of AI-based diagnostic modalities will require regulatory supervision, both related to the quality of the rendered diagnosis and the ultimate destination of the diagnostic information	6.83	7	Very strongly agree
As long as AI is used as a supportive method, ethical issues will be minor. However, when AI takes over tasks from the pathologist, i.e., making a diagnosis without human oversight, it will face major ethical challenges.	6.58	7	Very strongly agree
Pathologists will still be legally responsible for diagnoses made with the help of AI	6.25	7	Very strongly agree
Meeting regulatory requirements for most AI applications will be a lengthy and costly process, as it will involve large-scale prospective studies	5.46	5,5	Strongly agree
Definition of end-points for validation clinical studies will be a common problem	5.50	6	Strongly agree
Post-marketing surveillance will pose important challenges, due to algorithm drift	5.50	6	Strongly agree
Regulatory approval of AI tools used for definitive (primary) diagnosis will be very strict, but AI used for advisory purposes (secondary) will also have to meet strict regulatory conditions	6.04	6	Strongly agree
CLIA regulations and clarification surrounding the use of laboratory data within pathology and laboratory processes versus outside of the laboratory will be reviewed and updated	5.63	6	Strongly agree
Governments will actively promote innovation in the areas of AI and medicine, fostering the advancement of AI in pathology	5.88	6	Strongly agree
Legal disputes will often arise regarding who should assume liability (pathologist, institution, developer, commercial vendor) for diagnostic errors induced by AI	5.67	6	Strongly agree
Al and technology will be included in the educational curricula for medical students, pathologists, and analysts to help them deal with this rapidly evolving method of support and its ethical implications	5.88	6	Strongly agree
Hurried pathologists will often take "shortcuts" by accepting Al interpretations without verification	5.08	5	Agree

Potentially-biased algorithms due to lack of demographic diversity in training datasets will lead to diagnostic errors	5.13	5	Agree
Data inferences that may impact on patient anonymity will lead to ethical issues	5.17	5	Agree

- 462 AI, artificial intelligence; CLIA, Clinical Laboratory Improvement Amendments.
- 463

There was also agreement that the regulatory approval of adaptive algorithms, which continuously evolve in response to new input data, would be possible, but that algorithm drift would pose important challenges that would need to be tackled by close post-market surveillance. It was also anticipated that legal disputes would arise regarding who should assume liability for diagnostic errors induced by AI, with pathologists still being held legally responsible for AI-assisted diagnosis.

469

470 With regard to differences in opinion between the various panelist subgroups, the North American

471 panelists more strongly believed that CLIA regulations and clarification surrounding the use of

472 laboratory data within pathology, as well as laboratory processes, would need to be reviewed and

473 updated (p = 0.031; median = 6 vs. median = 5 and mean = 6 vs. mean = 5.18 for North American vs.

474 other panelists, respectively). Those subspecialized in informatics or computational/digital pathology
475 less strongly believed that legal disputes would often arise regarding who should assume liability for

- 476 diagnostic errors induced by AI (p = 0.018; mean = 4.88 and median = 5), compared to those not
- 477 subspecialized in those areas (mean = 6.06 and median = 6).
- 478

479 Overall, the panel acknowledged there would be major ethical issues arising from the full delegation of 480 tasks to AI algorithms, believing it likely that hurried pathologists would often accept AI interpretations 481 without sufficient verification. On the other hand, there was disagreement between the panelists 482 regarding whether the black box nature of AI algorithms would cause pathologists to often make 483 diagnoses without enough clinical explainability. The panelists who had been in practice fewer years (≤ 484 10 years) more strongly believed that ethical issues would result from data inferences which might 485 compromise patient anonymity (p = 0.004; mean = 6 and median = 6), compared to those in practice \geq 486 11 years (mean = 4.82 and median = 5).

487

Finally, there was general consensus that ethical issues were expected to arise due to: 1) risk for diagnostic error resulting from the use of potentially biased algorithms trained on datasets lacking sufficient demographic diversity; and 2) the lack of proper informed consent when using patient data (which the panel agreed would become a common practice). Nevertheless, the panelists expected official regulatory bodies would do their part to overcome the aforementioned ethical and legal challenges, and funding bodies would actively promote innovation in AI and medicine, thereby fostering

the advancement of AI in pathology. It was also anticipated AI would be integrated into both medical
school and continuing medical education curricula for pathologists in current practice, in order to help
them adapt to this rapidly evolving area and its associated legal and ethical implications.

497

498 DISCUSSION

499 From this first ever consensus study of a panel of 24 international experts with first-hand experience 500 working in the field of computational pathology and AI (almost all of whom are also pathologists in 501 active clinical practice), we obtained specific insight into consistently agreed-upon opportunities and 502 challenges, as well as perspectives and predictions, relevant to the expected role of AI in pathology 503 over the next decade. Our panel was composed of experts of both genders, practicing in 11 different 504 countries, specializing in a wide range of pathology subspecialties, and with a wide range of years in 505 practice (with all panelists having attending pathologist/faculty status). Despite this diversity in the 506 expert panel, the panelists were able to reach consensus agreement on 140 (78.3%) of the 180 items 507 surveyed.

508

509 There was particularly strong consensus AI would improve the KPI of diagnostic accuracy, at least 510 partially by assisting with the detection of rare events (such as small tumor foci and metastases), 511 standardizing the diagnosis and grading of tumors, and making histopathologic analyses more 512 guantitative. There was also particularly strong consensus that the number of specialized computational 513 pathologists would greatly increase, and that pathologists would be more involved in diagnostic tumor 514 boards and multidisciplinary conferences as a result of AI integration. Significant changes in the types 515 of tasks routinely performed by a pathology laboratory technician were also expected. It was projected 516 that laboratory technicians would be operating digital slide scanners and performing digital image 517 management and QA/QC daily.

518

519 It was felt to be almost certain that specific pathology AI applications would be in routine use by 2030 – 520 namely, algorithms for the identification of lymph node macro- and micro- metastases, IHC/IF stain 521 guantification (including Ki-67, ER, PgR, and PD-L1), mitosis guantification, and lymphocyte 522 guantification. It was also felt to be very likely that algorithms would be in routine use for: 1) specific 523 pre-analytical tasks, such as automated QA/QC of histologic preparation, WSI quality, and IHC 524 controls, automated suggestion or ordering of ancillary stains and molecular tests, and automated case 525 prioritization; 2) specific analytical tasks, such as pre-selection of cancer regions of interest and hotspot 526 areas, microorganism detection, tumor grading, eosinophil and feature quantification, tumor area

527 measurement, identification of lymphovascular and perineural invasion, diagnostic report 528 standardization, and ensuring that all diagnostically-relevant areas in a WSI are viewed prior to report 529 finalization; and (3) specific post-analytical tasks, such as enforcement of mandatory second reads 530 when there is a significant discrepancy between the pathologist-rendered and Al-rendered diagnoses. 531 The panelists felt it very likely that many of the preceding tasks, along with colorectal polyp and cervical 532 cytology screening, case triage and assignment to pathologists, and contextual electronic 533 health/medical records data lookup, would no longer be performed by pathologists in the year 2030, as 534 they will have been fully delegated to AI. These predictions are consistent with the relatively high representation of many available applications in the existing pathology AI research literature. 29,31,41,43,57-535 63 536

537

538 At the same time, it is interesting to note that many of the applications projected to be in routine use 539 within the next decade address basic or mundane tasks already being performed by pathologists. 540 rather than advanced or "aspirational" tasks pathologists do not currently perform (such as prediction of 541 molecular biomarker status or clinical outcomes directly from morphologic features on H&E-stained 542 slides). The relative projected likelihoods of these two dominant categories of AI applications ("basic" 543 versus "aspirational") being in routine use by 2030 seems, in many ways, contrary to the relative 544 degree of attention paid to these categories by the research community and industry stakeholders. ^{35,41,64–66} For example, in a recent survey from 2021,⁶⁷ 75 computational pathology domain experts from 545 academia and industry (48% with medical and 52% with non-medical backgrounds) were asked to 546 547 provide their subjective rankings regarding the degree of interest, importance, and/or promise of 12 548 solid tumor-specific pathology AI applications. Among the applications surveyed, those falling within the 549 advanced/aspirational categories were consistently rated the most highly, while those falling within the 550 more basic/mundane categories (such as QA/QC, tumor grading, and subtyping) were rated the lowest, 551 with the most highly-rated application being prediction of treatment response directly from H&E images, 552 followed by prediction of genetic mutations, gene expression, and survival directly from H&E images, 553 respectively. Although "degree of interest/importance/promise" is not exactly equivalent to the 554 "likelihood of routine near-term adoption", the somewhat discrepant findings between the two surveys, 555 each of which targeted different participant populations, suggests that those with non-medical and/or 556 industry backgrounds (who collectively formed the majority of participants in the cited study) might be 557 more optimistic about the near-term role and importance of advanced/"aspirational" AI applications in 558 pathology than pathologists with first-hand experience working in the areas of computational 559 pathology/AI, who tend to have a more practical perspective regarding those AI applications likely to 560 enjoy widespread adoption in the near to medium term. It was unclear from our study why more 561 advanced/"aspirational" AI tools were not predicted to be in routine use within the next decade.

Perhaps, it was felt that such tools, though interesting from a research standpoint, would never reach the level of performance required for clinical adoption. Or, in order to have a sufficient level of performance for these tools, the fundamental AI infrastructure addressing the "basic" tasks would have to be completed first, paving the way for full diagnostic AI algorithm clinical validation and regulatory clearance. It remains for future studies to explore the reasons underpinning the results observed in this (and other) surveys regarding clinical AI.

568

569 Only a few other studies have sought to survey the opinions of various stakeholders regarding Al in 570 pathology. In a 2018 survey of 363 practicing pathologists and 124 pathology trainees from 54 571 countries (46% female, 56% practicing in the United States, Canada, or the United Kingdom, and 43% 572 in practice for ≤ 10 years) on general perspectives regarding the integration of AI into diagnostic 573 pathology, 81% of respondents predicted that AI would be integrated into pathology workflows within 574 the next 5–10 years.³⁴ In the same survey, 38% of respondents felt that AI would have no impact on 575 pathologist employability, 42% felt that it would create new positions and improve employment 576 prospects, and 20% were either concerned or extremely concerned that AI would displace them from 577 their jobs. Approximately 72% of the respondents also felt that AI tools could increase or dramatically 578 increase diagnostic efficiency, with the remaining 28% being unsure of AI's impact on efficiency, or of 579 the opinion that AI would have either no impact or a negative impact on efficiency. In contrast to the 580 more heterogeneous respondent demographic in that survey, the participants in our survey were 581 composed almost exclusively of practicing pathologists with experience in computational pathology/AI. 582 Although the consensus perspectives from our survey were more optimistic regarding the impact of AI 583 on the pathologist workforce, there was similar reservation regarding whether AI integration would truly 584 lead to increased efficiency, in terms of cost per case (one of the KPI's which failed to reach consensus 585 in our study) and turnaround time per case (which failed to reach high directional consensus).

586

587 Finally, it is worth noting some of the areas where there was either a lack of consensus among the 588 panelists, or consensus toward a less optimistic perspective on the topic in question. There was a lack 589 of consensus regarding whether AI would reduce the cost per case or the number of cases requiring 590 pathologist review (after automated AI-based filtering of negative/normal cases), and whether it would 591 increase patient satisfaction. There was also a lack of consensus regarding many regulatory aspects 592 related to AI integration. For example, the panelists were uncertain whether it would become possible in 593 the near future for approved developers to circumvent the requirement for individual approval of each 594 new application, or whether legal and administrative barriers would be overcome regarding the use of 595 de-identified images for research and education. There was general agreement that regulatory issues 596 would still pose a challenge to the use of AI, even when the pathologist or another physician was the

597 final decision-maker regarding diagnosis, prognostication, or treatment. There were differences of 598 opinion surrounding several ethical aspects of AI integration, including whether AI outputs used for 599 clinical decision-making would always need to be manually reviewed by a pathologist, or whether other 600 healthcare professionals would start using AI tools to diagnose cases without the aid of a pathologist. 601 There was uncertainty around whether the "black box" nature of many AI tools would cause 602 pathologists to make diagnoses without enough clinical explainability, and a lack of consensus 603 regarding whether pathologists would occasionally make diagnoses contrary to their own judgment 604 because of AI software recommendations. There was also no consensus on whether AI would lead to 605 de-skilling of pathologists (a subject which remains controversial within the pathology community³⁴), or 606 whether it would be possible to ensure that pathologists took full responsibility for double-checking and 607 confirming Al-rendered diagnoses. Due to the current Al "translation gap" in pathology, there have been 608 either no, or only a limited number of, studies evaluating the impact of AI tools on pathologist behavior,^{25,26,59,68–71} laboratory cost expenditures, medicolegal liability, or patient satisfaction. Therefore, 609 610 the current lack of consensus among the panelists regarding the preceding topics is understandable 611 and expected to be resolved as (1) more AI tools reach maturity and come to be evaluated in 612 prospective clinical settings, and (2) more consideration is directed toward ensuring that AI models are 613 integrated into pathology workflows in a manner that maximizes accuracy, time and cost efficiency, safety, transparency, accountability, and positive impact on patient outcomes. 8,9,15,49,72 614

615

616 Our study was subject to several limitations. Given the voluntary nature of participation and the 617 substantial time commitment required to complete all three Delphi rounds, not all experts who were 618 initially invited agreed to participate in the study, introducing the possibility of non-response bias. In 619 addition, the proportion of female participants (16.7%) was much lower than the proportion of male 620 participants. Although out of the 39 candidates originally invited to participate in this study 15 (38.9%) 621 were women, possibly reflecting a relative underrepresentation of women in the pathology informatics 622 and more specifically, the computational pathology/AI space, finally only four completed our survey. 623 Only one of the participants was a cytopathologist (who also subspecialized in other areas of anatomic 624 pathology), which may reflect the current underrepresentation of this subspecialty in computational 625 pathology/AI due to the challenges of generating and storing z-stacked WSIs (which may resolve with 626 the introduction of dedicated cytology whole-slide scanners in the near future).⁴² Also, as most of the 627 participants were practicing in North America and Europe, the results of this study may reflect a 628 predominantly North American/European perspective that differs from the perspectives of those 629 practicing in other parts of the world. Lastly, as our study was targeted toward a specific respondent 630 demographic, individuals from other stakeholder groups (such as pathology trainees, pathologists with 631 little or no experience in computational pathology/AI, pathology laboratory technicians, computer

scientists and others working in the computational pathology/AI space with non-medical backgrounds,
physicians in other specialties, and patients) were not represented in our results. We anticipate all
above issues to be sufficiently addressed in forthcoming studies, and that our survey, with its freelyavailable data collection forms, may serve as a model study for independent validation and extension.

636

637 We hope the results of this first systematic consensus study have provided a detailed vision of what 638 pathology might look like in the year 2030, from the point of view of those with first-hand experience 639 developing and evaluating clinical AI tools. Furthermore, we feel this study lays the groundwork for 640 future follow-up studies in 3-5 years' and 10 years' time, assessing the evolution of expectations and 641 challenges as the field of computational pathology progresses. Clearly, AI is expected to have a deep 642 impact on the specialty of pathology, with several pathology AI applications anticipated to be in routine 643 use by 2030, including some that will fully replace pathologists on specific tasks. The results of our 644 study provide detailed insight into the current challenges, expectations, and perspectives surrounding 645 the near to medium term role of AI in pathology, including timely and relevant information regarding 646 how pathology care might be delivered in the future, assuming all regulatory and ethical questions are addressed.^{48,73} We expect these findings will be of broad interest to a wide variety of stakeholders, 647 648 including pathologists, pathology trainees and laboratory technicians, hospital administrators, 649 researchers in academia, industry, and government, patients, professional societies, and regulatory

- 650
- 651
- 652

657

666

653 **REFERENCES** 654

bodies.

1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.* 2019;**25(1)**:44–56. doi: 10.1038/s41591-018-0300-7, PMID 30617339.

Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare [internet]. *Nat Med.* 2019;**25(1)**:24–9. doi: 10.1038/s41591-018-0316-z, PMID 30617335.

Meskó B, Görög M. A short guide for medical professionals in the era of artificial intelligence. *NPJ Digit Med.* 2020;**3**:126. doi: 10.1038/s41746-020-00333-z, PMID 33043150.

4. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. *J Intern Med*. 2020;**288(1)**:62–81. doi: 10.1111/joim.13030, PMID 32128929.

5. Berbís MA, Aneiros-Fernández J, Mendoza Olivares FJM, Nava E, Luna A. Role of artificial
intelligence in multidisciplinary imaging diagnosis of gastrointestinal diseases [internet]. *World J Gastroenterol.* Jul 21, 2021;27(27):4395–412. doi: 10.3748/wjg.v27.i27.4395, PMID 34366612.

671 6. Rajpurkar P, Chen E, Banerjee O, Topol EJ. Al in health and medicine. *Nat Med.*672 2022;**28(1)**:31–8. doi: 10.1038/s41591-021-01614-0, PMID 35058619.

673 674 7. Abels E, Pantanowitz L, Aeffner F, et al. Computational pathology definitions, best practices, 675 and recommendations for regulatory guidance: a white paper from the Digital Pathology Association. J 676 Pathol. 2019;249(3):286-94. doi: 10.1002/path.5331, PMID 31355445. 677 678 Müller H, Holzinger A, Plass M, Brcic L, Stumptner C, Zatloukal K. Explainability and causability 8. 679 for artificial intelligence-supported medical image analysis in the context of the European in vitro 680 diagnostic regulation. New Biotechnol. 2022;70:67-72. doi: 10.1016/j.nbt.2022.05.002, PMID 681 35526802. 682 683 9. McGenity C, Treanor D. Guidelines for clinical trials using artificial intelligence – SPIRIT-AI and 684 CONSORT-AI. J Pathol. 2021;253(1):14-6. doi: 10.1002/path.5565, PMID 33016344. 685 686 10. FDA. Artificial intelligence/machine learning (AI/ML)-based software as a medical device 687 (SaMD) action plan, p. 1–7: Jan 12, 2021 [cited Jun 7, 2022]. Available from: https://www.fda.gov/media/145022/download. 688 689 690 FDA authorizes software that can help identify prostate cancer; Sep 21, 2021. FDA news 11. 691 release [cited Jun 7, 2022]. Available from: https://www.fda.gov/news-events/press-692 announcements/fda-authorizes-software-can-help-identify-prostate-cancer. 693 694 12. Das R. Five technologies that will disrupt healthcare by 2020. Forbes [cited Jun 7, 2022]. 695 Available from: https://www.forbes.com/sites/reenitadas/2016/03/30/top-5-technologies-disrupting-696 healthcare-by-2020/?sh=5b175d246826; Mar 30, 2016. 697 698 Khosla V. Technology will replace 80% of what doctors do. Fortune [cited Jun 7, 2022]. 13. 699 Available from: https://fortune.com/2012/12/04/technology-will-replace-80-of-what-doctors-do/; Dec 4, 700 2012. 701 702 14. Longoni C, Morewedge CK. AI can outperform doctors. So why don't patients trust it? Harv Bus 703 *Rev.* Oct 30, 2019. 704 705 Jackson BR, Ye Y, Crawford JM, et al. The ethics of artificial intelligence in pathology and 15. 706 laboratory medicine: principles and practice. Acad Pathol. 2021;8:2374289521990784. doi: 707 10.1177/2374289521990784. PMID 33644301. PMCID PMC7894680. 708 709 16. Vought RT, Office of Management and Budget. Memorandum for the heads of executive 710 departments and agencies: guidance for regulation of artificial intelligence applications. White House 711 *memo*. Jan 2020;**7**:1–15. 712 713 Ailia MJ, Thakur N, Abdul-Ghafar J, Jung CK, Yim K, Chong Y. Current trend of artificial 17. 714 intelligence patents in digital pathology: A systematic evaluation of the patent landscape. Cancers. 715 2022;14(10):2400. doi: 10.3390/cancers14102400, PMID 35626006. 716 717 Hida AI. Omanovic D. Pedersen L. et al. Automated assessment of Ki-67 in breast cancer: the 18. 718 utility of digital image analysis using virtual triple staining and whole slide imaging. *Histopathology*. 719 2020;77(3):471-80. doi: 10.1111/his.14140, PMID 32578891. 720 721 19. Saha M. Chakraborty C. Arun I. Ahmed R. Chatteriee S. An advanced deep learning approach 722 for Ki-67 stained hotspot detection and proliferation rate scoring for prognostic evaluation of breast 723 cancer. Sci Rep. 2017;7(1):3213. doi: 10.1038/s41598-017-03405-5, PMID 28607456. 724

725 20. Yousif M, van Diest PJ, Laurinavicius A, et al. Artificial intelligence applied to breast pathology. 726 Virchows Arch. 2022;480(1):191–209. doi: 10.1007/s00428-021-03213-3. PMID 34791536. 727 728 Xu H, Park S, Hwang TH. Computerized classification of prostate cancer Gleason scores from 21. 729 whole slide images. IEEE ACM Trans Comput Biol Bioinform. 2020;17(6):1871-82. doi: 730 10.1109/TCBB.2019.2941195, PMID 31536012. 731 732 22. Bulten W, Pinckaers H, van Boven H, et al. Automated deep-learning system for Gleason 733 grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol. 2020;21(2):233-41. doi: 734 10.1016/S1470-2045(19)30739-9, PMID 31926805. 735 736 23. Nagpal K, Foote D, Liu Y, et al. Development and validation of a deep learning algorithm for 737 improving Gleason scoring of prostate cancer. NPJ Digit Med. 2019;2:48. doi: 10.1038/s41746-019-738 0112-2, PMID 31304394. 739 740 Ström P, Kartasalo K, Olsson H, et al. Artificial intelligence for diagnosis and grading of prostate 24. 741 cancer in biopsies: a population-based, diagnostic study. Lancet Oncol. 2020;21(2):222-32. doi: 742 10.1016/S1470-2045(19)30738-7, PMID 31926806. 743 744 25. Pantanowitz L, Quiroga-Garza GM, Bien L, et al. An artificial intelligence algorithm for prostate 745 cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and 746 deployment study. Lancet Digit Health. 2020;2(8):e407-16. doi: 10.1016/S2589-7500(20)30159-X, 747 PMID 33328045. 748 749 26. Steiner DF, MacDonald R, Liu Y, et al. Impact of deep learning assistance on the 750 histopathologic review of lymph nodes for metastatic breast cancer. Am J Surg Pathol. 751 2018;42(12):1636–46. doi: 10.1097/PAS.0000000000001151, PMID 30312179. 752 753 27. Ehteshami Beinordi B. Veta M. Johannes van Diest P. et al. Diagnostic assessment of deep 754 learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA. 755 2017;318(22):2199-210. doi: 10.1001/jama.2017.14585, PMID 29234806. 756 757 Campanella G, Hanna MG, Geneslaw L, et al. Clinical-grade computational pathology using 28. 758 weakly supervised deep learning on whole slide images. Nat Med. 2019;25(8):1301-9. doi: 759 10.1038/s41591-019-0508-1, PMID 31308507. 760 761 29. Yousif M, van Diest PJ, Laurinavicius A, et al. Artificial intelligence applied to breast pathology. 762 Virchows Arch. 2022;480(1):191–209. doi: 10.1007/s00428-021-03213-3, PMID 34791536. 763 764 30. Haymond S, McCudden C. Rise of the machines: artificial intelligence and the Clinical 765 Laboratory. J Appl Lab Med. 2021;6(6):1640-54. doi: 10.1093/jalm/jfab075, PMID 34379752. 766 Haghighat M, Browning L, Sirinukunwattana K, et al. Automated quality assessment of large 767 31. 768 digitised histology cohorts by artificial intelligence. Sci Rep. 2022;12(1):5002. doi: 10.1038/s41598-022-08351-5, PMID 35322056. 769 770 771 32. Janowczyk A, Zuo R, Gilmore H, Feldman M, Madabhushi A. HistoQC: an open-source quality 772 control tool for digital pathology slides. JCO Clin Cancer Inform. 2019;3:1–7. doi: 773 10.1200/CCI.18.00157, PMID 30990737, PMCID PMC6552675. 774

775 33. Mitchell BR, Cohen MC, Cohen S. Dealing with multi-dimensional data and the burden of 776 annotation: easing the burden of annotation. Am J Pathol. 2021;191(10):1709-16. doi: 777 10.1016/j.ajpath.2021.05.023, PMID 34129843. 778

779 34. Sarwar S, Dent A, Faust K, et al. Physician perspectives on integration of artificial intelligence 780 into diagnostic pathology. NPJ Digit Med. 2019;2:28. doi: 10.1038/s41746-019-0106-0, PMID 781 31304375.

782 783 35. Cheng JY, Abel JT, Balis UGJ, McClintock DS, Pantanowitz L. Challenges in the development. 784 deployment, and regulation of artificial intelligence in anatomic pathology. Am J Pathol. 785 2021;191(10):1684–92. doi: 10.1016/j.ajpath.2020.10.018, PMID 33245914. 786

787 36. Tizhoosh HR, Pantanowitz L. Artificial intelligence and digital pathology: challenges and 788 opportunities. J Pathol Inform. 2018;9:38. doi: 10.4103/jpi.jpi 53 18, PMID 30607305. 789

790 Steiner DF, Chen PC, Mermel CH. Closing the translation gap: AI applications in digital 37. 791 pathology. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188452. doi: 792 10.1016/j.bbcan.2020.188452, PMID 33065195. 793

794 Sobhani F, Robinson R, Hamidinekoo A, Roxanis I, Somaiah N, Yuan Y. Artificial intelligence 38. 795 and digital pathology: opportunities and implications for immuno-oncology. Biochim Biophys Acta Rev 796 Cancer. 2021;1875(2):188520. doi: 10.1016/j.bbcan.2021.188520, PMID 33561505.

798 39. Serag A, Ion-Margineanu A, Qureshi H, et al. Translational AI and deep learning in diagnostic 799 pathology. Front Med (Lausanne). 2019;6:185. doi: 10.3389/fmed.2019.00185, PMID 31632973. 800

801 40. Rakha EA, Toss M, Shiino S, et al. Current and future applications of artificial intelligence in 802 pathology: a clinical perspective. J Clin Pathol. 2021;74(7):409-14. doi: 10.1136/jclinpath-2020-206908, 803 PMID 32763920. 804

805 41. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital 806 pathology — new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16(11):703–15. 807 doi: 10.1038/s41571-019-0252-y, PMID 31399699. 808

809 42. Flach RN, Fransen NL, Sonnen AFP, et al. Implementation of artificial intelligence in diagnostic 810 practice as a next step after going digital: the UMC Utrecht perspective. Diagnostics (Basel). 811 2022;**12(5)**:1042. doi: 10.3390/diagnostics12051042, PMID 35626198. 812

813 43. Farris AB, Vizcarra J, Amgad M, Cooper LAD, Gutman D, Hogan J. Artificial intelligence and 814 algorithmic computational pathology: an introduction with renal allograft examples. *Histopathology*. 815 2021;78(6):791-804. doi: 10.1111/his.14304. PMID 33211332. 816

817 44. Kriegsmann M, Haag C, Weis CA, et al. Deep learning for the classification of small-cell and 818 non-small-cell lung cancer. Cancers (Basel). 2020;12(6):1604. doi: 10.3390/cancers12061604, PMID 819 32560475. 820

821 45. van der Laak J, Litjens G, Ciompi F. Deep learning in histopathology: the path to the clinic. Nat 822 *Med.* 2021;**27(5)**:775–84. doi: 10.1038/s41591-021-01343-4. PMID 33990804.

824 46. Homeyer A, Lotz J, Schwen LO, et al. Artificial intelligence in pathology: from prototype to 825 product. J Pathol Inform. 2021;12:13. doi: 10.4103/jpi.jpi 84 20, PMID 34012717. 826

797

823

47. Försch S, Klauschen F, Hufnagl P, Roth W. Artificial intelligence in pathology. *Dtsch Arztebl Int.*2021;**118(12)**:194–204. doi: 10.3238/arztebl.m2021.0011, PMID 34024323.

48. Kearney SJ, Lowe A, Lennerz JK, et al. Bridging the gap: the critical role of regulatory affairs
and clinical affairs in the total product life cycle of pathology imaging devices and software. *Front Med (Lausanne).* 2021;8:765385. doi: 10.3389/fmed.2021.765385, PMID 34869473.

49. Chauhan C, Gullapalli RR. Ethics of AI in pathology: current paradigms and emerging issues. *Am J Pathol.* 2021;**191(10)**:1673–83. doi: 10.1016/j.ajpath.2021.06.011, PMID 34252382.
836

837 50. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its
838 appropriateness. *World J Methodol.* 2021;**11(4)**:116–29. doi: 10.5662/wjm.v11.i4.116, PMID 34322364.
839

840 51. Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. *Int J*841 *Forecast.* 1999;**15(4)**:353–75. doi: 10.1016/S0169-2070(99)00018-7.
842

52. Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and Reporting
Delphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic
review. *Palliat Med.* 2017;**31(8)**:684–706. doi: 10.1177/0269216317690685, PMID 28190381.

53. Goodman CM. The Delphi technique: a critique. *J Adv Nurs*. 1987;**12(6)**:729–34. doi:
10.1111/j.1365-2648.1987.tb01376.x, PMID 3320139.

846

849

852

856

859

54. Dalkey NC, Helmer O. An experimental application of the Delphi method to the use of experts. *Manag Sci.* 1963;**9(3)**:458–67. doi: 10.1287/mnsc.9.3.458.

55. De Vet E, Brug J, De Nooijer J, Dijkstra A, De Vries NK. Determinants of forward stage
transitions: a Delphi study. *Health Educ Res.* 2005;**20(2)**:195–205. doi: 10.1093/her/cyg111, PMID
15328302.

857 56. von der Gracht HA. Consensus measurement in Delphi studies. *Technol Forecast Soc Change.*858 2012;**79(8)**:1525–36. doi: 10.1016/j.techfore.2012.04.013.

57. Holmström O, Linder N, Kaingu H, et al. Point-of-care digital cytology with artificial intelligence
for cervical cancer screening in a resource-limited setting. *JAMA Netw Open*. 2021;**4(3)**:e211740. doi:
10.1001/jamanetworkopen.2021.1740, PMID 33729503.

S8. Cheng S, Liu S, Yu J, et al. Robust whole slide image analysis for cervical cancer screening
using deep learning. *Nat Commun.* 2021;**12(1)**:5639. doi: 10.1038/s41467-021-25296-x, PMID
34561435.
867

868 59. Nasir-Moin M, Suriawinata AA, Ren B, et al. Evaluation of an artificial intelligence-augmented
869 digital system for histologic classification of colorectal polyps. *JAMA Netw Open*. 2021;**4(11)**:e2135271.
870 doi: 10.1001/jamanetworkopen.2021.35271, PMID 34792588.
871

872 60. lizuka O, Kanavati F, Kato K, Rambeau M, Arihiro K, Tsuneki M. Deep learning models for
873 histopathological classification of gastric and colonic epithelial tumours. *Sci Rep.* 2020;**10(1)**:1504. doi:
874 10.1038/s41598-020-58467-9, PMID 32001752.
875

Forlano R, Mullish BH, Giannakeas N, et al. High-throughput, machine learning–based
 quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with

878 nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(9):2081-2090.e9. doi: 879 10.1016/j.cgh.2019.12.025, PMID 31887451. 880 881 62. Heinemann F, Birk G, Stierstorfer B. Deep learning enables pathologist-like scoring of NASH 882 models. Sci Rep. 2019;9(1):18454. doi: 10.1038/s41598-019-54904-6, PMID 31804575. 883 884 63. Chatrian A, Colling RT, Browning L, et al. Artificial intelligence for advance requesting of 885 immunohistochemistry in diagnostically uncertain prostate biopsies. Mod Pathol. 2021;34(9):1780-94. 886 doi: 10.1038/s41379-021-00826-6, PMID 34017063. 887 888 64. Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in 889 translational medicine and clinical practice. Mod Pathol. 2022;35(1):23-32. doi: 10.1038/s41379-021-890 00919-2, PMID 34611303. 891 892 Wulczyn E. Steiner DF. Moran M. et al. Interpretable survival prediction for colorectal cancer 65. 893 using deep learning. NPJ Digit Med. 2021:4(1):71. doi: 10.1038/s41746-021-00427-2, PMID 33875798. 894 895 66. Sobhani F, Robinson R, Hamidinekoo A, Roxanis I, Somaiah N, Yuan Yinyin. Artificial 896 intelligence and digital pathology: opportunities and implications for immuno-oncology. Biochim Biophys 897 Acta Rev Cancer. 2021;1875(2):188520, ISSN 0304-419X. doi: 10.1016/j.bbcan.2021.188520, PMID 898 33561505. 899 900 67. Heinz CN, Echle A, Foersch S, Bychkov A, Kather JN. The future of artificial intelligence in 901 digital pathology – results of a survey across stakeholder groups. *Histopathology*. 2022;80(7):1121–7. 902 doi: 10.1111/his.14659, PMID 35373378. 903 904 68. Kiani A, Uyumazturk B, Rajpurkar P, et al. Impact of a deep learning assistant on the 905 histopathologic classification of liver cancer. NPJ Digit Med. 2020;3:23. doi: 10.1038/s41746-020-0232-906 8, PMID 32140566. 907 908 Zhou S, Marklund H, Blaha O, et al. Deep learning assistance for the histopathologic diagnosis 69. 909 of Helicobacter pylori. Intell-Based Med. 2020;1-2:(100004). doi: 10.1016/j.ibmed.2020.100004. 910 911 70. Dov D, Assaad S, Syedibrahim A, et al. A hybrid human-machine learning approach for 912 screening prostate biopsies can improve clinical efficiency without compromising diagnostic accuracy. 913 Arch Pathol Lab Med. 2022;146(6):727–34. doi: 10.5858/arpa.2020-0850-OA, PMID 34591085. 914 915 71. Steiner DF, Nagpal K, Sayres R, et al. Evaluation of the use of combined artificial intelligence 916 and pathologist assessment to review and grade prostate biopsies. JAMA Netw Open. 917 2020;3(11):e2023267. doi: 10.1001/jamanetworkopen.2020.23267, PMID 33180129. 918 919 72. Murphy K, Di Ruggiero E, Upshur R, et al. Artificial intelligence for good health: a scoping 920 review of the ethics literature. BMC Med Ethics. 2021;22(1):14. doi: 10.1186/s12910-021-00577-8, 921 PMID 33588803. 922 923 73. Marble HD, Huang R, Dudgeon SN, et al. A regulatory science initiative to harmonize and 924 standardize digital pathology and machine learning processes to speed up clinical innovation to 925 patients. J Pathol Inform. 2020;11:22. doi: 10.4103/jpi.jpi 27 20, PMID 33042601. 926 927